Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in November 2021
November 11 2021 - 8:00AM
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage
biopharmaceutical company focused on the discovery, development and
commercialization of innovative therapies for diseases of the eye,
today announced that management will participate in the following
virtual healthcare investor conferences in November 2021:
Jefferies London Healthcare ConferenceA
pre-recorded fireside chat will be made available on the company’s
website beginning Thursday, November 18, 2021 at 3:00 am ET/8:00 am
GMT. Management will also be available for virtual one-on-one
meetings on that date.
To access the webcast and subsequent archived recording of the
Jefferies fireside chat, please visit “Events” in the “Investors”
section on the Kala website at http://kalarx.com/.
Ophthalmology Day at BTIGManagement will
participate in a virtual fireside chat moderated by Tom Shrader,
PhD, CFA, BTIG Biotechnology Analyst at 10:00am ET and host virtual
one-on-one meetings on Tuesday, November 30, 2021.
BTIG hosted events are intended for prospective and existing
BTIG clients only. To listen to the live event, please contact your
BTIG representative with interest.
About Kala Pharmaceuticals,
Inc.
Kala is a commercial-stage biopharmaceutical company focused on
the discovery, development, and commercialization of innovative
therapies for diseases of the eye. Kala has applied its AMPPLIFY®
mucus-penetrating particle (MPP) Drug Delivery Technology to two
ocular therapies, EYSUVIS® (loteprednol etabonate ophthalmic
suspension) 0.25% for the short-term (up to two weeks) treatment of
signs and symptoms of dry eye disease and INVELTYS® (loteprednol
etabonate ophthalmic suspension) 1% for the treatment of
post-operative inflammation and pain following ocular surgery. The
Company also has a pipeline of pre-clinical development programs
targeted to address unmet medical needs, including both front and
back of the eye diseases. For more information on Kala, please
visit www.kalarx.com.
Investor Contacts: Jill
Steierjill.steier@kalarx.com781-996-5252
Hannah Deresiewiczhannah.deresiewicz@sternir.com
212-362-1200
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From May 2024 to Jun 2024
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Jun 2023 to Jun 2024